Obstetrics & Gynecology

News and Events

Programs and providers of Obstetrics and Gynecology at Weill Cornell Medicine are often the focus of news stories and features appearing in major national media. We invite you to review some stories that typify the breakthrough accomplishments of our remarkable team and highlight the impact our care has had on patient’s lives.

Dr. Elizabeth Kim Wins 2026 Tri-Institutional Breakout Award

Two women pose for a photo in a lab

Dr. Elizabeth Kim, a research associate in anesthesiology at Weill Cornell Medicine, has received a 2026 Tri-Institutional Breakout Award for Junior Investigators.

Weill Cornell Medicine, The Rockefeller University and Memorial Sloan Kettering Cancer Center present the awards annually, recognizing exceptional investigators for their remarkable research achievements, impactful findings and high potential for success as independent investigators. The winners, at least one from each institution, receive a $25,000 unrestricted prize.

“It’s an incredible honor to receive this recognition for my work,” said Dr. Kim, who received her doctorate in biochemistry and molecular biology at Louisiana State University School of Medicine. “It will have a major impact on my future career progression.”

A Breakthrough Single-Cell Method for Mapping DNA-Protein Interactions

space filling model of transcription factor bound to DNA

A new technology allows scientists to map, in single cells, the DNA binding sites of transcription factors and other regulatory proteins that control gene activity, according to a study led by investigators at Weill Cornell Medicine and the New York Genome Center. With key advantages over methods currently in use, the technology is expected to be a powerful addition to biologists’ toolkit for studying cells in health and disease.

“D&D-seq,” as the new method is called, uses antibodies to bring a DNA-editing enzyme close to a target protein, allowing researchers to record where that protein interacts with DNA. The study describing the technique, published June 4 in Cell, showed that it surmounts key technical drawbacks of current methods for mapping protein-DNA interactions, and is the first of its kind that can be easily incorporated into high-throughput, single-cell “multi-omics” workflows.

Oral Drug Combination Eases Treatment Burden for AML Patients

elderly AML patient

The ASCERTAIN V clinical trial demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia (AML) is an effective alternative to the current standard, which requires repeated hospital or office visits for intravenous treatment. In the international phase 1/phase 2 trial led by researchers at Weill Cornell Medicine, NewYork-Presbyterian, The University of Texas MD Anderson Cancer Center and Yale University, patients took a regimen of two pills, decitabine-cedazuridine and venetoclax, with strong response rates and survival outcomes. The study results were published June 3 in the New England Journal of Medicine.

Nearly half of patients (46.5%) achieved complete response, while 63% experienced either complete response or complete response with incomplete hematologic recovery, meaning cancer cells were undetectable, but the patient's healthy blood cell counts had not yet returned to normal. The median overall survival reached 15.5 months—comparable to existing intravenous therapies.

Contact Us